Acquired activated protein C resistance in sarcoma patients

Blood Coagulation and Fibrinolysis

Volumn 23, Issue 5, 2012, Pages 428-433

  Soyer, Nur ^a   Kececi, Burcin ^a   Eroglu, Zuhal ^a   Kamer, Serra ^b   Ozcelik, Cagri ^a   Cagirgan, Seckin ^a   Tombuloglu, Murat ^a   Sabah, Dundar ^a   Donmez, Ayhan ^a  

^a Department of Hematology ^*  (Turkey)

^b EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

acquired activated protein C resistance; malignancy; sarcoma; thrombosis

Indexed keywords

ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8;

ACQUIRED ACTIVATED PROTEIN C RESISTANCE; ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; AGED; ALVEOLAR SOFT PART SARCOMA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE CONTROL STUDY; CHEMORADIOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MUTATION; OSTEOSARCOMA; PLEOMORPHIC SARCOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SARCOMA; SOFT TISSUE SARCOMA; SPINDLE CELL SARCOMA; SYNOVIAL SARCOMA; VENOUS THROMBOEMBOLISM;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CASE-CONTROL STUDIES; CHILD; FACTOR V; FACTOR VIII; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROSPECTIVE STUDIES; SARCOMA; TIME FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84863316044     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3283548e19     Document Type: Article

References (37)

1. Khorana AA, Francis CW, Culakova E, Kuderer NM, LymanGH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007; 110:2339-2346. (Pubitemid 350100757)
2. Connolly GC, Khorana AA. Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. Thromb Res 2010; 125 (SUPPL. 2):S1-S7.
3. Furie B, Furie BC. Cancer-associated thrombosis. Blood Cells Mol Dis 2006; 36:177-181.
4. Lee AY. Epidemiology and management of venous thromboembolism in patients with cancer. Thromb Res 2003; 110:167-172. (Pubitemid 37338288)
5. Franchini M, Montagnana M, Targher G, Manzato F, Lippi G. Pathogenesis, clinical and laboratory aspects of thrombosis in cancer. J Thromb Thrombolysis 2007; 24:29-38. (Pubitemid 46831561)
6. Paz-Priel I, Long L, Helman LJ, Mackall CL, Wayne AS. Thromboembolic events in children and young adults with pediatric sarcoma. J Clin Oncol 2007; 25:1519-1524. (Pubitemid 46733078)
7. Athale U, Siciliano S, Thabane L, Pai N, Cox S, Lathia A, et al. Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer. Pediatr Blood Cancer 2008; 51:792-797.
8. Mitchell SY, Lingard EA, Kesteven P, McCaskie AW, Gerrand CH. Venous thromboembolism in patients with primary bone or soft-tissue sarcomas. J Bone Joint Surg Am 2007; 89:2433-2439. (Pubitemid 350086333)
9. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993; 90:1004-1008. (Pubitemid 23053939)
10. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85:1504-1508.
11. de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93:1271-1276. (Pubitemid 29076142)
12. Bertina R, Koeleman B, Koster T, Rosendaal F, Dirven R, Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64-67. (Pubitemid 24144355)
13. Haim N, Lanir N, Hoffman R, Haim A, Tsalik M, Brenner B. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med 2001; 110: 91-96. (Pubitemid 32126427)
14. Zangari M, Saghafifar F, Anaissie E, Badros A, Desikan R, Fassas A, et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 2002; 13:187-192. (Pubitemid 35001883)
15. Jiménez-Zepeda VH, Doḿnguez-Mart́nez VJ. Acquired activated protein C resistance and thrombosis in multiple myeloma patients. Thromb J 2006; 4:11.
16. Elice F, Fink L, Tricot G, Barlogie B, Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 2006; 134:399-405. (Pubitemid 44079553)
17. Nijziel MR, van Oerle R, Christella M, Thomassen LG, van Pampus EC, Hamulyák K, et al. Acquired resistance to activated protein C in breast cancer patients. Br J Haematol 2003; 120:117-122. (Pubitemid 36056918)
18. Sarig G, Michaeli Y, Lanir N, Brenner B, Haim N. Mechanisms for acquired activated proteinCresistance in cancer patients. J Thromb Haemost 2005; 3:589-590. (Pubitemid 41632885)
19. Negaard HF, Iversen PO, Ostenstad B, Mowinckel MC, Sandset PM. Increased acquired activated protein C resistance in unselected patients with hematological malignancies. J Thromb Haemost 2008; 6:1482-1487.
20. Zwicker JI, Furie BC, Furie B. Cancer-associated thrombosis. Crit Rev Oncol Hematol 2007; 62:126-136. (Pubitemid 46575277)
21. Castoldi E, Rosing J. APC resistance: biological basis and acquired influences. J Thromb Haemost 2010; 8:445-453.
22. Nijziel MR, van Oerle R, Thomassen LG, Hamulyák K, Tans G, Rosing J. Acquired resistance to activated protein C in breast cancer patients. Thromb Haemost 1999; 82(Abstract 980):311.
23. Henkens CMA, Bom VJJ, van der Meer J. Lowered APC-sensitivity ratio related to increased factor VIII-clotting activity. Thromb Haemost 1995; 74:1198; (letter).
24. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapyassociated thrombosis. Blood 2008; 111:4902-4907.
25. Wramsby ML, Bokarewa MI, Blombäck M, Bremme AK. Response to activated protein C during normal menstrual cycle and ovarian stimulation. Hum Reprod 2000; 15:795-797. (Pubitemid 30192725)
26. van Vliet HA, Rodrigues SP, Snieders MN, van der Meer FJ, Frolich M, Rosendaal FR, et al. Sensitivity to activated protein C during the menstrual cycle in women with and without factor V Leiden. Thromb Res 2008; 121:757-761. (Pubitemid 351491293)
27. van Rooijen M, Silveira A, Thomassen S, Odeberg J, Hamsten A, Rosing J, et al. APC resistance during the normal menstrual cycle. Thromb Haemost 2007; 98:1246-1251. (Pubitemid 350239096)
28. Trigg DE, Wood MG, Kouides PA, Kadir RA. Hormonal influences on hemostasis in women. Semin Thromb Hemost 2011; 37:77-86.
29. Male C, Mitchell L, Julian J, Vegh P, Joshua P, Adams M, et al. Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2001; 97:844-849. (Pubitemid 32154263)
30. Rosendaal FR. High levels of factor VIII and venous thrombosis. Thromb Haemost 2000; 83:1-2. (Pubitemid 30045465)
31. Kurekci AE, Gokce H, Akar N. Factor VIII levels in children with thrombosis. Pediatr Int 2003; 45:159-162. (Pubitemid 36578933)
32. Orhon FŞ, Egin Y, Ulukol B, Başkan S, Akar N. The relation between soluble endothelial protein C receptor and factor VIII levels and FVIII/sEPCR index in healthy infants. Turk J Hematol 2011; 28:27-32.
33. Vurkun M, Vural Ö, Demir M, Turgut B, Gürgey A, Parlak H, et al. The prevalence of activated protein C resistance and F V Leiden in healthy population of Edirne, Turkey. Turk J Hematol 2002; 19:287-291. (Pubitemid 35221295)
34. Payzin B, Adakan FY, Yalçin HC, Cetinkaya GS, Berkmen S, Eraslan S, et al. Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease. Turk J Gastroenterol 2006; 17:183-190. (Pubitemid 46568097)
35. Ay M, Dolek B, Erdem G, Devecioglu O, Gozukirmizi N. Is there any correlation between the elevated plasma levels and gene variations of factor VIII in Turkish thrombosis patients? Clin Appl Thromb Hemost 2011; 17:46-50.
36. Souto JC, Almasy L, Borrell M, Garí M, Mart́nez E, Mateo J, et al. Genetic determinants of hemostasis phenotypes in Spanish families. Circulation 2000; 101:1546-1551. (Pubitemid 30180891)
37. Bossone A, Cappucci F, D'Andrea G, Brancaccio V, Cibelli G, Iannaccone L, et al. The factor V (FV) gene ASP79HIS polymorphism modulates FV plasma levels and affects the activated protein C resistance phenotype in presence of the FV Leiden mutation. Haematol 2003; 88:286-289. (Pubitemid 36358716)